
Keywords: ارزیابی اقتصادی بهداشتی; CF; cystic fibrosis; CFTR; cystic fibrosis transmembrane conductance regulator; CRD; Centre of Research and Dissemination; DNA; deoxyribonucleic acid; HAS; Haute Autorité de Santé; HTA; health technology assessment; ICER; incremental cost effectiveness